美股市场个股详情

ORGO Organogenesis

添加自选

2.390
-0.100-4.02%

收盘价 05/06 16:00 (美东)

2.390
0.000-0.01%

盘后 18:49 (美东)

3.17亿总市值59.75市盈率TTM

Organogenesis股票讨论区

登录发表评论

Stock Region

05/03 02:26

Therapeutics Company Achieves Promising Clinical Trial Results For Knee Osteoarthritis Therapy

The implications of ReNu’s success extend far beyond symptom management.
Organogenesis Holdings Inc., a frontrunner in the regenerative medicine landscape, has recently shared groundbreaking results from its Phase 3 clinical trial for ReNu®, a cutting-edge therapy designed for knee osteoarthritis (OA) management. The trial's positive top line data underscore a pivotal moment in pain management and regen...

Jaguar8

05/02 19:04

$Organogenesis(ORGO.US)$
NEWS
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee ...

beachlover

04/04 23:22

$Organogenesis(ORGO.US)$ 🔥HUBC🔥

Moomoo AI

03/04 22:06

Despite poor earnings, the high P/E ratio indicates investors anticipate strong future growth, justifying a higher stock price. Unless earnings significantly deteriorate, the share price should remain strong.

Organogenesis Holdings Inc.'s (NASDAQ:ORGO) P/E Is On The Mark

Moomoo AI

01/14 20:42

Albert Erani's recent sale of Organogenesis Holdings shares, the largest insider sale in the past year, raises concerns despite the high sale price. The absence of insider buying and presence of selling suggest a cautious outlook, despite high insider ownership.

Have Insiders Sold Organogenesis Holdings Shares Recently?

StaNnnn

2023/12/15 12:14

Looking Forward... It is a good setup

$Organogenesis(ORGO.US)$

GAME_DAY

2023/09/29 01:03

Current watch ⚡️

$欧朋公司(OPRA.US)$ $大健云仓(GCT.US)$ $Sunrun(RUN.US)$ $车车科技(CCG.US)$ $Lululemon Athletica(LULU.US)$ $Aytu BioPharma(AYTU.US)$ $Organogenesis(ORGO.US)$ $Genasys(GNSS.US)$ $Bionomics(BNOX.US)$ $Sirius XM(SIRI.US)$

逍遥投资派

2023/05/26 23:08

$Organogenesis(ORGO.US)$营收5年来总体高速增长，平均增速为17.9%，2022年略微萎缩3.5%，营业利润2020年扭亏，2021年达到0.72亿的高点，2022年大幅下滑69%，净利润也类似，2021年达到0.94亿的高点，2022年大幅下滑83.5%到0.155亿。
利润表显示2022年营收虽然下滑，但是营业费用却继续高速增长造成了营业利润的大幅下滑。利息费用占营业利润的9%，负担不算太重。
2023Q1营收增长10.8%，营业利润进入亏损区间，还是由于营业费用增加过快造成的，看起来公司费用控制能力非常差劲。
5年来资产负债率从71.3%下降到40.9%。
资产负债率显示应收和存货比例和增速都比较正常，长期借款0.66亿，占净资产的25%，杠杆率正常。
5年来现金流经营净额累计还是净流出状态，还有大笔的现金流投资净流出，没有产生股东盈余。
目前31.8倍市盈率，34.6倍市盈率TTM，可以再观察几份财报，着重看营业费用占比情况是否有所改善再做判断。